General Information of DTT (ID: TTDP48B)

DTT Name Bromodomain-containing protein 2 (BRD2) DTT Info
Gene Name BRD2

Molecule-Related Drug & Molecule List

Molecule-Related Drug List
Molecule Type:
DTT
DTP
DME
Drug Status:
Clinical Trial Drug(s)
Patented Agent(s)
Investigative Drug(s)
2 Clinical Trial Drug(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
OTX-015 DMI8RG1 Acute myeloid leukaemia 2A60 Phase 1/2 [1]
ABBV-744 DMTEA9C Acute myeloid leukaemia 2A60 Phase 1 [2]
------------------------------------------------------------------------------------
6 Patented Agent(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
PMID26924192-Compound-102 DMEJ107 N. A. N. A. Patented [3]
PMID26924192-Compound-103 DMWOCP7 N. A. N. A. Patented [3]
PMID26924192-Compound-104 DM346EU N. A. N. A. Patented [3]
PMID26924192-Compound-105 DMAWLGI N. A. N. A. Patented [3]
PMID26924192-Compound-106 DM9HRZJ N. A. N. A. Patented [3]
Pyrrolo-pyrrolone derivative 1 DMN4SE5 N. A. N. A. Patented [3]
------------------------------------------------------------------------------------
⏷ Show the Full List of 6 Patented Agent(s)
9 Investigative Drug(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
BIC1 DMFS2V9 Discovery agent N.A. Investigative [4]
ET bromodomain inhibitor DMH4MBW Discovery agent N.A. Investigative [5]
GW841819X DMRL9IN Discovery agent N.A. Investigative [6]
I-BET151 DMYRUH2 Discovery agent N.A. Investigative [7]
ME bromodomain inhibitor DMMFYP9 Discovery agent N.A. Investigative [5]
PMID21851057C4d DMI1FGV Discovery agent N.A. Investigative [8]
PMID24000170C36 DMHUWZS Discovery agent N.A. Investigative [9]
PMID24000170C38 DMOLRIY Discovery agent N.A. Investigative [9]
XD14 DMUMACD Discovery agent N.A. Investigative [10]
------------------------------------------------------------------------------------
⏷ Show the Full List of 9 Investigative Drug(s)
Molecule Interaction Atlas

References

1 Targeting bromodomains: epigenetic readers of lysine acetylation.Nat Rev Drug Discov.2014 May;13(5):337-56.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22.
4 Real-time imaging of histone H4K12-specific acetylation determines the modes of action of histone deacetylase and bromodomain inhibitors. Chem Biol. 2011 Apr 22;18(4):495-507.
5 Chemical biology. A bump-and-hole approach to engineer controlled selectivity of BET bromodomain chemical probes. Science. 2014 Oct 31;346(6209):638-41.
6 Discovery and characterization of small molecule inhibitors of the BET family bromodomains. J Med Chem. 2011 Jun 9;54(11):3827-38.
7 Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. Nature. 2011 Oct 2;478(7370):529-33.
8 3,5-dimethylisoxazoles act as acetyl-lysine-mimetic bromodomain ligands. J Med Chem. 2011 Oct 13;54(19):6761-70.
9 Naphthyridines as novel BET family bromodomain inhibitors. ChemMedChem. 2014 Mar;9(3):580-9.
10 4-Acyl pyrroles: mimicking acetylated lysines in histone code reading. Angew Chem Int Ed Engl. 2013 Dec 23;52(52):14055-9.